Baker Bros. Advisors LP Gamida Cell Ltd. Transaction History

Baker Bros. Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.22 - $4.47 $1.36 Million - $2.73 Million	-610,626 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$5.85 - $8.33 $2.5 Million - $3.55 Million	-426,600 Reduced 41.13%	610,626 $3.91 Million
Q1 2021 May 17, 2021	SELL	$7.8 - $12.43 $3.99 Million - $6.35 Million	-511,088 Reduced 33.01%	1,037,226 $8.39 Million
Q4 2020 Feb 16, 2021	BUY	$4.07 - $11.0 $3.72 Million - $10.1 Million	914,990 Added 144.47%	1,548,314 $13 Million
Q3 2020 Nov 16, 2020	SELL	$3.93 - $4.59 $131,034 - $153,039	-33,342 Reduced 5.0%	633,324 $2.63 Million

Q2 2020 Aug 14, 2020	BUY	$2.79 - $6.5 $1.86 Million - $4.33 Million	666,666 New	666,666 $3.05 Million

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.